Lineage Cell Therapeutics, Inc. Common Stock (LCTX)
Stock-Based Compensation
$5.07M
TTM · Period ending: · USD
LCTX Stock-Based Compensation
Latest reported$5.07Mperiod ending
Latest reported$5.07Mperiod ending
LCTX TTM Stock-Based Comp ($0.00 → $5.07M)
TTM stock-based compensation
High-resolution chart · PNG
LCTX stock-based compensation history
Trailing twelve months (TTM) · USD. Each value covers four complete reported quarters.
| Period ending | Stock-Based Compensation (USD) |
|---|---|
| 5,070,000 | |
| 4,707,000 | |
| 4,752,000 | |
| 4,969,000 | |
| 5,100,000 | |
| 5,131,000 | |
| 5,077,000 | |
| 4,822,000 | |
| 4,761,000 | |
| 4,772,000 | |
| 4,640,000 | |
| 4,539,000 | |
| 4,257,000 | |
| 4,212,000 | |
| 4,287,000 | |
| 4,246,000 | |
| 4,402,000 | |
| 4,086,000 | |
| 3,519,000 | |
| 3,095,000 | |
| 2,453,000 | |
| 2,140,000 | |
| 2,227,000 | |
| 2,352,000 | |
| 2,610,000 | |
| 2,766,000 | |
| 3,580,000 | |
| 4,966,000 | |
| 5,517,000 | |
| 5,858,000 | |
| 5,402,000 | |
| 4,426,000 | |
| 4,089,000 | |
| 3,890,000 | |
| 3,932,000 | |
| 4,551,000 | |
| 4,288,000 | |
| 5,604,000 | |
| 7,951,000 | |
| 10,164,000 | |
| 12,943,000 | |
| 12,508,593 | |
| 11,050,000 | |
| 8,323,647 | |
| 5,943,279 | |
| 5,568,273 | |
| 4,455,420 | |
| 4,163,294 | |
| 4,078,221 | |
| 3,448,554 | |
| 3,217,875 | |
| 2,671,092 | |
| 2,019,797 | |
| 1,537,324 | |
| 1,282,507 | |
| 1,375,896 | |
| 1,271,945 | |
| 1,244,040 | |
| 1,217,522 | |
| 1,037,669 | |
| 914,661 | |
| 789,423 | |
| 638,709 | |
| 793,541 | |
| 703,669 | |
| 595,852 | |
| 488,564 | |
| 258,976 | |
| 203,543 | |
| 166,056 | |
| 173,882 | |
| 190,423 | |
| 196,146 | |
| 213,114 | |
| 224,587 | |
| 187,508 | |
| 181,785 | |
| 164,817 | |
| 129,030 | |
| 161,320 | |
| 161,320 | |
| 161,320 | |
| 161,320 | |
| 15,050 | |
| 15,050 | |
| 15,050 | |
| 48,276 | |
| 48,276 | |
| 48,276 | |
| 48,276 | |
| 38,750 | |
| 230,670 | |
| 230,670 | |
| 230,670 | |
| 191,920 | |
| 0 | |
| 0 | |
| 0 | |
| 0 | |
| 0 |